Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.36 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.36 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074438 | 1.00 | RAPGEF4 (0.41) | RAPGEF4AHRNOTUMTSHRTDP1 | |
| SCHEMBL15512406 | 0.82 | CA1 (0.37) | RAPGEF4AHRNOTUMTDP1ADORA2A | |
| SCHEMBL321756 | 0.82 | AHR (0.52) | RAPGEF4AHRNOTUMTSHRTDP1 | |
| SCHEMBL81205 | 0.82 | CES2 (0.46) | RAPGEF4TSHRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL3786224 | 0.82 | RAPGEF4 (0.47) | RAPGEF4AHRNOTUMTSHRTDP1 | |
| SCHEMBL2159227 | 0.82 | CES2 (0.40) | RAPGEF4TSHRTDP1ALDH1A1CYP3A4 | |
| Nitrogen SCHEMBL9592328 | 0.77 | AHR (0.48) | RAPGEF4AHRNOTUMTSHRTDP1 | |
| Nitrogen SCHEMBL28987389 | 0.75 | AHR (0.47) | RAPGEF4AHRNOTUMTSHRTDP1 | |
| SCHEMBL30074464 | 0.73 | RXRA (0.36) | TSHRALDH1A1CES2HDAC3HDAC1 | |
| SCHEMBL18260731 | 0.73 | RXRA (0.36) | TSHRALDH1A1CES2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646215-B | Process for the preparation of 3-trifluoromethyl chalcones | 杜邦公司 | 2020-04-14 | — | — | CN | claimed |
| US-9938248-B2 | Method for preparing 3-trifluoromethyl chalcones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2018-04-10 | — | — | US | claimed |
| US-20180057468-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | CORTEVA AGRISCIENCE LLC | 2018-03-01 | — | — | US | claimed |
| EP-2706050-B1 | 1-Chloro-3-iodo-5-(trifluoromethyl)benzene | DU PONT (US) | 2016-08-31 | — | — | EP | claimed |
| US-20140155617-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-06-05 | — | — | US | claimed |
| EP-2706050-A1 | 1-Chloro-3-iodo-5-(trifluoromethyl)benzene | E. I. du Pont de Nemours and Company (US) | 2014-03-12 | — | — | EP | claimed |
| US-20110009638-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2260016-A2 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E. I. du Pont de Nemours and Company (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2009126668-A2 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-10-15 | — | — | WO | claimed |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-119176772-A | Compound with Mrgpr X receptor inhibition effect and application thereof | 博济医药科技股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-12-19 | — | — | US | disclosed |
| WO-2013185084-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| US-8546618-B2 | Method for preparing 3-trifluoromethyl chalcones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| CN-101990530-A | Process for the preparation of 3-trifluoromethyl chalcones | DU PONT | 2011-03-23 | — | — | CN | disclosed |
| US-20110009638-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2260016-A2 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E. I. du Pont de Nemours and Company (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009126668-A2 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155617-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | NR3C2, RAE1, SULT1E1 | RAPGEF4 1026/4885AHR 2688/4885NOTUM 999/4885 |
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | RAPGEF4 1108/4885AHR 3648/4885NOTUM 4170/4885 |
| US-20180057468-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | NR3C2, CYP4A11, RAE1 | RAPGEF4 817/4885AHR 2262/4885NOTUM 1579/4885 |
| US-20110009638-A1 | METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES | NR3C2, CYP4A11, RAE1 | RAPGEF4 817/4885AHR 2262/4885NOTUM 1579/4885 |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | RAPGEF4 2483/4885AHR 3364/4885NOTUM 3757/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | RAPGEF4 2702/4885AHR 3950/4885NOTUM 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.